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Abstract 
The aim of this work was to formulate chitosan (CS) based nanoparticles (NPs) loaded with 
ketorolac tromethamine (KT) intended for topical ocular delivery. NPs were prepared using 
ionic gelation method incorporating tri-polyphosphate (TPP) as cross-linker. Following the 
preparation, the composition of the system was optimised in terms of their particle size, zeta 
potential, entrapment efficiency (EE) and morphology, as well as performing structural 
characterisation studies using FT-IR and DSC. The data suggested that the size of the NPs 
was affected by CS/TPP ratio where the diameter of the NPs ranged from 108.0 ± 2.4 nm to 
257.2 ± 18.6 nm. A correlation between drug EE and the corresponding drug concentration 
added to the formulation was observed, where the EE of the NPs increased with increasing 
drug concentration, for up to 10 mg/mL. FT-IR and DSC revealed that KT was dispersed 
within the NPs where the phosphate groups of TPP were associated with the ammonium 
groups of CS. The in vitro release profile of KT from CS NPs showed significant differences 
(P<0.05) compared to KT solution. Furthermore, mucoadhesion studies revealed adhesive 
properties of the formulated NPs. The KT loaded NPs were found to be stable when stored at 
different storage conditions for a period of 3 months. The ex vivo corneal permeation studies 
performed on excised porcine eye balls confirmed the ability of NPs in retaining the drug on 
the eye surface for a relatively longer time. These results demonstrate the potential of CS 
based NPs for the ocular delivery of KT. 
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Introduction  
Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug (NSAID) from the 
family of heterocyclic acetic acid derivatives (Li et al., 2015). It is effective in inhibiting 
post-operative eye inflammation, reducing conjunctivitis with no alteration of corneal 
opacity,  yet has been shown to increase intraocular pressure (Sunil et al., 2013). KT is a non-
selective cyclooxygenase (COX) inhibitor, being marketed as a racemate mixture (Savaroglu 
& Genc, 2013). It is administered as its tromethamine salt orally, intramuscularly, 
intravenously and as a topical ophthalmic solution (Sinha et al., 2009). KT is available as a 
topical ophthalmic solution (0.4% - 0.5% w/v), tablets (10 mg) and solution for injection (15-
30 mg/ml). Topical KT is a more effective inhibitor of miosis than topical diclofenac sodium 
during cataract surgery (Unlu et al., 2010).  
Only small amounts (1% - 3% w/v) of ophthalmic solutions such as those of  KT eye drops 
penetrate the cornea and reaches intraocular tissues. Also,  side effects of KT including 
gastrointestinal bleeding, perforation and peptic ulceration along with the short mean plasma 
half-life (t1/2  ͠ 5.5 h) has prompted research for the development of improved  formulations of 
KT (Sinha, et al., 2009). 
Most efforts in ophthalmic drug delivery have been devoted to increasing the corneal 
penetration of drugs with the final goal of improving the efficacy of treatments of different 
ocular diseases (Nagai et al., 2015). These attempts included the use of colloidal drug 
delivery systems, such as liposomes and biodegradable nanoparticles (NPs) and 
nanocapsules. However, the short precorneal residence time of these colloidal systems 
represents a limitation for treatment of ocular surface diseases, such as conjunctivitis and dry 
eye  (Achouri et al., 2013). Substantial efforts have been directed towards the development of 
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ocular drug delivery systems that would prolong the drug precorneal residence, thus 
increasing ocular bioavailability (Abdelkader et al., 2014; Rupenthal, 2011). 
NPs for ophthalmic drug delivery have been shown to enhance the ocular bioavailability 
while providing sustained release action (Hafner et al., 2015). There have been studies over 
the years examining the mechanism of drug release and reporting on ocular therapeutic 
efficacy of drugs delivered using nanoparticles (Zhu et al., 2012). Furthermore, such drug  
delivery systems are advocated as an ophthalmic drug delivery systems that may enhance 
dosage form acceptability while providing sustained release action (Kaur & Smitha, 2002). 
Polymeric nanoparticles (PNPs) enable manipulation of surface properties for site-targeting 
of drugs; improve overall stability, enhance safety and efficiency for local and systemic drug 
delivery (Abdelkader et al., 2012). Their nanometre–size promotes effective permeation 
through membrane barriers enabling enhanced bioavailability. They have been shown to 
cross mucosal barriers, i.e. the intestinal, nasal and ocular membranes (Zhang & Zhao, 2015). 
Chitosan (CS), obtained (from marine crustaceans) via the deacetylation of chitin is a 
naturally occurring and abundantly available polysaccharide (Ngo et al., 2015). 
Commercially available CS has an average molecular weight ranging between 3800 and 
20,000 Daltons and is 66% to 95% deacetylated (Agnihotri et al., 2004). CS exhibits many 
advantages when used to formulate NPs for drug delivery applications, including 
biocompatibility, biodegradability, and low immunogenicity. The high positive charge 
density also confers its mucoadhesive properties and renders it attractive for mucosal drug 
delivery. CS possesses amino group on the D-glucosamine residue which upon protonation 
forms an electrostatic bond with negatively charged sialic acid on mucin. Thus, the 
interaction between mucin and CS, which is related to the electrostatic charge of both the 
molecules usually affect mucoadhesive characteristics of CS, depending on the pH of the 
 
 
4 
  
media (Silva et al., 2012). According to the Henderson–Hasselbach equation, the degree of 
ionisation of CS and mucin at pH 5 was 96.93% and 99.75% respectively (Qaqish & Amiji, 
1999). Felt et al. (1999) identified CS as a well-tolerated mucoadhesive cationic polymer that 
affects epithelial pathways of the ocular tissues and thus, increasing the permeability of drug, 
making it suitable for the development of ocular dosage forms (Felt et al., 1999). Also, CS  
has a relatively low toxicity in ocular delivery; which has been confirmed by Di Colo et al. 
(2004) who described the absence of apparent irritation signs following topical instillation of 
CS solution (Di Colo et al., 2004). Its LD50 in laboratory mice is 16 g/kg body weight, which 
is close to sugar and salt (Karthikeyan et al., 2013). It has been reported that CS has wound 
healing properties, permeability enhancing characteristics as it enhances drug permeation 
through the cornea by opening the tight junctions between epithelial cells (Almeida et al., 
2014). Furthermore, it has antimicrobial properties and is used in the production of wound 
healing dressings (Almeida et al., 2013). Thus, CS is considered as the most suitable polymer 
for the formulation of ophthalmic dosage forms (Fabiano et al., 2015). Therefore, CS-NPs are 
considered to be promising carrier systems for the drug and gene delivery. In addition, CS 
has special properties such as protonation of its amine groups under acidic condition; it can 
be cross-linked with other polymers such as tripolyphosphate (TPP) (Hassani et al., 2015) 
and sodium alginate to form NPs. The preparation of CS NPs via the cross-linking method 
was found to be simple and mild as reported previously by (Ji et al., 2011). 
This paper discusses the design and characterisation of CS based NPs for the ocular delivery 
of KT. The specific objectives include:  
 Investigating effect of formulation parameters on the size, size distribution and 
morphology along with physicochemical and spectroscopic characterisation of the 
formed CS-TPP NPs. 
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 Establishing the effect of drug concentration on the percentage entrapment efficiency 
(EE%); and conducting the in vitro release study of KT from prepared CS-TPP NPs.  
 Studying the mucoadhesive properties and ex vivo permeation of KT across excised 
porcine corneas as well as testing the physical stability of prepared NPs at different 
storage conditions. 
 
Experimental 
Materials 
Ketorolac tromethamine (KT), low molecular weight chitosan (deacetylation degree 85%, 
viscosity 20,000 cP), sodium tripolyphosphate (TPP) and porcine mucin were purchased from 
Sigma Aldrich chemicals Co., UK. Glacial acetic acid was purchased from Fisher Scientific, 
UK. All other solvents and buffer salts were obtained from Sigma Aldrich chemical Co., UK; 
were of analytical grade and used as received. 
Preparation of chitosan-sodium tripolyphosphate nanoparticles (CS-TPP NPs) 
CS-NPs were prepared using the ionic gelation method, previously reported by Calvo. et 
al.(Calvo et al., 1997b). In brief, CS solutions were prepared by sonication at various 
concentrations (1, 1.25, 1.75, and 2 mg/mL) in dilute acetic acid (1% v/v) at room 
temperature; the pH of the formed solution was 3.2. The pH of the CS solution was adjusted 
to pH 5.5 with 1M NaOH as at this pH, CS is ionised. Then, the solution was filtered using 
0.45 µm filter membrane. An aqueous solution of 4 mL of TPP at various concentrations i.e. 
0.5, 0.75, and 1 mg/mL was added drop wise to 10 mL CS solution with magnetic stirring 
(900 rpm for 30 min) at room temperature to yield a final volume ratio of (2.5:1 v/v) of 
CS:TPP.  
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Particle size and zeta potential measurement 
The particle size and Poly Dispersity Index (PDI) of the prepared NPs were determined by 
dynamic light scattering (DLS) using Malvern Zetasizer 3000HSA at 25
o
C.  Zeta potential 
was measured by Laser Doppler Electrophoresis (LDE) using the same instrument under the 
same conditions. Size values were reported as mean hydrodynamic diameter (MHD). All 
measurements were undertaken on at least three independent preparations.  
Physicochemical characterisation of prepared nanoparticles 
 Scanning electron microscopy (SEM) 
Morphological examination of KT-loaded CS-NPs was performed using Zeiss EVO 50, 
tungsten source SEM. A drop of NPs suspension was spread on a 10 mm glass cover slip 
which was fixed onto an aluminium support stub, air-dried and sputter coated with 
gold/palladium alloy. NPs morphology was determined at 20.00 kV. 
 Differential scanning calorimetry (DSC)  
The thermal analysis of CS, KT, the physical mixture (PM) of both CS and KT and also the 
freeze-dried powder of the KT-loaded NPs was carried out on Mettler Toledo DSC 822e0, 
Switzerland. The calorimeter was calibrated with indium; samples were weighed separately 
in aluminium pans; covered with aluminium lids and hermitically sealed using a pan press 
(Thermal Science, USA). Once in the calorimeter, the temperature of the pan was gradually 
increased from 25
o
C to 300
o
C at a rate of 10
o
C/min. Nitrogen was purged at a flow rate of 45 
mL/min. The data generated was consolidated using Mettler STARe software version 8.10. 
Freeze drying of selected CS-NPs was carried out using TELSTAR – CRYODOS-I-
rev0105MA freeze dryer (Telstar Industrial, S. L., Spain). Freeze dried samples were 
generated by subjecting 15 mL of NPs formulation to two drying steps following freezing. 
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 Fourier Transform Infrared Spectroscopy (FT-IR)   
FT-IR spectrometer (Thermo Scientific Nicolet iS5, Thermo fisher, USA) was used to record 
the FT-IR spectra of CS, KT, their PM and freeze-dried powder of KT-loaded NPs. A clean 
diamond window was used to measure the background spectra. Sufficient amount (approx. 2-
4 mg) of the sample was placed to form a thin film covering the diamond window. The FT-IR 
spectra were recorded at a resolution of 2 cm
-1
 with an average of 120 scans. The data was 
acquired and analysed using Omnic software (Omnic version 8.2, USA). 
HPLC analysis of KT 
Isocratic HPLC separation was achieved using reversed phase Phenominex C18 column 
(150mm×4.6mm×5µm).The mobile phase consisted of methanol and phosphate buffer (pH 3) 
with ratio of 55:45 v/v respectively and was selected to achieve good separation and 
resolution. A flow rate of 1 mL/min and injection volume of 10 µL were used to give an 
optimal signal-to-noise ratio with a reasonable separation time and run time was 20 min. The 
detection was performed at 314 nm. 
Determination of drug entrapment efficiency 
 The NPs were separated from the aqueous medium that contained free drug by centrifuging 
the samples at 12,000 × g for a period of 30 min at 4
o
C. This was followed by the 
redispersion of NPs in PBS (pH 7.4). Varying amounts of KT were used (5, 10, and 15 
mg/mL) and its effect on selected NPs ratio was determined. The content of KT in the 
supernatant was measured using HPLC method. The entrapment efficiency (EE%) of the NPs 
was determined using equation 1. All experiments were performed in triplicates.  
Entrapment Efficiency (EE %) =
(Tp – Tf)
Tp
 ×  100                  Equation 1 
 
 
8 
  
Where, Tp is the total amount of KT used  in the preparation of NPs and Tf is the free KT 
present in the supernatant (Soppimath K.S et al., 2001). 
 
Stability and mucoadhesion studies  
The stability and mucoadhesive properties of KT loaded CS-NPs were investigated through 
incubation of these NPs with porcine mucin. Two in vitro methods were used in this study. 
The first method was based on the measurement of the viscosity of mucin dispersion 
(0.4mg/mL) in water before and after incubation at 35
o
C in the presence of CS-NPs or CS 
solutions. Dispersion viscosity measurements were carried out by Brookfield viscometer 
(DV-ΙΙ +Pro, USA). For each time interval, three measurements were taken, and average 
values were computed. The second method was employed to evaluate the influence of the 
mucin on the zeta potential of NPs. CS-NPs were incubated at 35
o
C in an aqueous solution of 
mucin under stirring. At predetermined time intervals (0, 30, 60, and 120 min) during 
incubation, the zeta potential of the NPs was determined. Equal volumes of mucin solution 
(0.4 mg/mL) and CS-NPs as well as CS solution were vortexed for 1 min and the zeta 
potential of the mixtures were measured by Zetasizer (De Campos et al., 2004). 
In vitro release study 
In vitro release studies were performed using standard Franz diffusion cells. The Franz–
diffusion cells had a 15 mm diameter orifice (providing a diffusion area of 1.7 cm
2
) and were 
thermostated by means of a water jacket connected to a VTC-220 heat circulator (Logan 
Instrument Corporation, Somerset, NJ, USA). Receptor chambers (12 mL volume) were 
filled with phosphate buffer (PBS, pH 7.4; osmolality 297 mOSm/kg) and stirred constantly 
using small magnetic bars. The donor and the receptor compartments were separated by a 
dialysis (cellophane) membrane with a molecular weight cut-off of 12,000-14,000 Da. The 
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membrane was pre-soaked in the receptor medium overnight prior to the experiment. The 
temperature was set at 35
o
C ± 0.5
o
C. The centrifuged samples i.e. each formulation 
consisting of 1 mL of the NP dispersion in PBS (pH 7.4) loaded with 5 mg of KT was placed 
in the donor compartment before occluding the chamber with Parafilm. 1 mL samples were 
withdrawn at predetermined time intervals for up to 6 h, and replaced with an equal volume 
of fresh receptor medium. The amount of KT released at each time point was determined by 
HPLC method.  
Ex vivo permeation study  
Corneas used in the ex vivo experiments were obtained from porcine eye balls, which were 
freshly collected from a local abattoir. The eyes were examined for any visual defects. They 
were kept in a normal saline solution, directly transported to the laboratory and used within 
few hours of enucleation. Corneo-scleral buttons were dissected using standard eye bank 
techniques, and care was taken to minimise tissue distortion. Franz diffusion cell was used 
and the tissue was placed between the donor and the receiver compartments with the 
endothelial side facing the receptor compartment; temperature was maintained at 35
o
C. The 
receiver compartment and the donor compartment were filled with 12 mL of PBS solution 
(pH 7.4), and 1 mL of the formulation respectively. For each formulation, three corneas were 
used (n = 3). Samples (1 mL) were withdrawn from the receiver compartment for analysis of 
drug permeation at predetermined time points, and were replaced with fresh PBS solution to 
compensate the withdrawn sample volume. The amount of KT that permeated across the 
cornea was quantified by HPLC method (Gratieri et al., 2011).  
Ex vivo data analysis 
The apparent permeability coefficient (Papp, cm/s) was calculated according to the following 
equation (Abdelkader et al., 2011). 
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 ACot
Q
Papp
3600

   Equation 2 
Where ∆Q/∆t is the permeability rate constant of KT across the excised porcine corneas. It 
was calculated from the gradient of the plot of the amount of KT permeated (Q) versus time 
(t); Co is the initial drug concentration (µg/mL), A is the corneal surface area (cm
2
) in contact 
with the formulation from the epithelial side and the release media from the endothelial side 
and 3600 is a factor used for the conversion of hours to seconds. The lag time (tL) was 
determined by extrapolating the linear plot to the x-axis. 
 
Stability of the prepared nanoparticles 
Samples of the drug loaded NPs were stored in clean, capped 20 mL glass vials at three 
different temperatures (4oC, 22
o
C and 40oC) for three months. At specified time intervals, the 
stored samples were visually inspected for appearance, change in the colour and were also 
evaluated for change in the pH and particle size. The EE% of the stored samples was also 
determined after the 3 month time point. 
Statistical analysis 
Statistical analysis was performed using a one-way analysis of variance (ANOVA) by 
GraphPad Software Version 3.05, USA. A p value of < 0.05 was considered to be statistically 
significant. 
Results and discussion  
Two different pH conditions were used in this study. The NPs were prepared at pH 5.5 
initially as at this pH CS is highly ionised enabling dissolution. Once the NPs are formed, 
they were dispersed in PBS, pH7.4, which is the final formulation pH as the normal pH of the 
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tear fluid is between 6.5 and 7.4. The NPs were mixed with PBS to yield a final KT 
concentration of 5 mg/mL. As reported by Ludwig et al. (2005), it is necessary that the pH 
and tonicity of the solution instilled onto the ocular surface is physiologically compatible to 
minimise tissue irritation, reflex tearing and blinking, as this may lead to a loss of the dose. 
Also, any disturbance in the physiological pH of tear fluid results in increased blinking rate 
and lacrimation. Therefore, the pH of the ophthalmic preparations is adjusted close to the 
natural pH of the tear fluid to minimise irritation of the eye surface (Ludwig, 2005). 
Particle size and zeta potential measurements 
Results (Table 1) showed that the particle size is dependent on CS concentration, with size 
reduction being proportional to the CS concentration. At CS concentration of 1 mg/mL, the 
mean particle size was 108.0 ± 2.4 nm (F1), upon increasing CS concentration to 2 mg/mL, 
the average particle size increased to 257.2 ± 18.6 nm (F7). Thus, showing a significant 
difference (P < 0.001) between F7 and other formulations. The same applied when the CS 
concentration was increased from 1.25 mg/mL to 1.75 mg/mL, without altering the 
concentration of TPP (0.5 mg/mL); the size of the F4 and F6 formulations increased 
significantly (P < 0.01; Table1), which is an indication of dependence of the size of the NPs 
on the CS/TPP ratio (Aydın & Pulat, 2012). According to Zhao et al., the success of CS-NPs 
with nano-sized scale, the concentration of CS and TPP should be controlled at a suitable 
range (Zhao & Wu, 2006). Also, it is well accepted that the particle size of ocular 
formulations should not exceed 10 µm in order to avoid eye irritation as well as foreign body 
sensation. In addition, Zhou et al. (2013) reported that NPs with size range between 1 nm and 
1000 nm improved passage of poorly water soluble drugs through the ocular tissues (Zhou et 
al., 2013). Also, ibuprofen loaded Eudragit RS100 nanosuspension with a mean particle size 
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of 100 nm and with a positive zeta potential has been successfully tested for ophthalmic 
applications previously (Pignatello et al., 2002).  
The poly dispersity index (PDI) for all the prepared formulations ranged between 0.111 ± 
0.041 and 0.274 ± 0.157, thus complying with the accepted limits (less than 0.4) of PDI. This 
indicates a relatively narrow particle size distribution and uniformity of the prepared NPs. 
The difference in the PDI values was found to be insignificant (P > 0.05) among the NP 
formulations (Table 1).  
The increase in the mass ratio of CS led to an increase of the particle zeta potential. This was 
presumed to be due to the availability of free (unbound) amino groups on the CS molecule, 
contributing to an increased positive charge (Ji, et al., 2011). However, an increase in the TPP 
concentration led to a decrease in zeta potential and an increase in particle size as shown in 
(Table 1). For formulation F1, the zeta potential was found to be 22.9 ± 0.95 mV, however, 
when the TPP concentration was increased, as seen in F3, the zeta potential decreased 
significantly (P < 0.05) to 16.6 ± 0.26 mV. This decrease in the zeta potential was thought to 
be due to the neutralisation of positive charge contributed by the amino groups of CS 
molecule upon interaction with the negatively charged phosphate groups on TPP. However, 
upon comparing F1 and F7 formulations, there was no significant difference (P > 0.05) in 
their zeta potential values as the mass ratios for these two formulations were kept constant. 
On the other hand, when the CS concentration was doubled (formulation F7) in relation to 
formulation F3, a significant increase (P < 0.001) in the zeta potential was noted (Table 1). 
From the literature (Calvo, et al., 1997b), it is known that increasing CS concentrations as 
well as TPP concentrations will lead to increasing particle diameters and agglomeration of 
the produced NPs and similar observations were made in the present study. 
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The effect of changing the pH of CS solution from around (3.0 to 5.5) on the average particle 
size as well as zeta potential of prepared NPs was investigated. The size of the NPs increased, 
presumably due to the aggregation of particles as CS is highly protonated at pH 5.5. On the 
other hand, the zeta potential of the NPs decreased with increasing the pH of CS solution 
which may be due to the decreased positive charge density of the polymer with the rise in the 
pH, Figure 1. Our results are in agreement with the previous reports (Ji, et al., 2011); it 
suggests that the most suitable pH for NPs formation in this study would be pH 5.5. 
Entrapment of KT in CS-TPP nanoparticles 
The effect of different concentration of KT on the average particle size, surface charge and 
EE% of the prepared NPs has been investigated. It is clear from Table 2 that the average 
particle size of the NPs has been increased upon loading the drug compared to drug free NPs. 
Moreover, the particle size appeared to increase significantly (P < 0.05) with increasing 
concentration of KT i.e. from 5mg/mL to 10 mg/mL. Incorporation of KT into the NPs had 
an influence on the zeta potential as with formulations F4KT and F7KT the zeta potential 
decreased significantly (P < 0.01) upon incorporation of KT compared with drug free NPs i.e. 
F4 and F7, respectively (Table 1).  This indicates an electrostatic interaction between the drug 
and CS. This is in agreement with what has been reported by Boonsongrit et al. (2006). The 
EE% of KT has increased upon increasing drug concentration (Table 2). When KT was 
loaded into the formulations at a concentration of 5 mg/mL, a significantly lower (P < 0.001) 
EE% was noted for formulation F1KT (5.23 ± 2.14) compared to the remaining NP 
formulations tested at this KT concentration. The EE% among the remaining formulations 
ranged between 18.60 ± 0.32 and 35.03 ± 4.40 with F2KT yielding a significantly (P < 0.05) 
higher entrapment than others barring F6KT. On the other hand, a significant increase (P < 
0.001) in the EE%, i.e. from 22.0 ± 3.80 to 71.70 ± 1.55 was noted for F3KT formulation, 
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when the drug concentration was increased from 5mg/mL to 10 mg/mL respectively. The 
entrapment of KT within the NPs is presumed to be primarily that of matrix type. In addition, 
drug adsorption on the surface of NPs may also take place. DSC results (Figure 4) showed 
disappearance of the endothermic peak of KT indicating dispersion of KT in a molecular 
form due to electrostatic interaction and H-bonding between polymers used in the 
formulation process and the drug. Also, this has been confirmed by the decrease in the zeta 
potential of the NP formulations upon incorporation of different concentrations of KT (Table 
2). 
 
Effect of drug concentration on the Entrapment Efficiency  
 
Drug loading into NPs has been optimised by varying drug concentrations i.e. 5, 10, and 15 
mg/mL of KT. Data in Figure 2 demonstrate that increasing the concentration of KT within 
F2KT formulation from 5mg/mL to 10 mg/mL, there was a pronounced enhancement in the 
entrapment efficiency (EE%) (P < 0.05). However, when drug concentration was further 
increased to 15 mg/mL for the same formulation, the NPs did not show a significant variation 
in EE% (P > 0.05). Moreover, the drug precipitated within the NP dispersion presumably due 
to the drug concentration reaching the saturation capacity within NPs at a concentration of 10 
mg/mL. Thus, increasing KT concentration during NP preparation from 5 mg/mL to 10 
mg/mL showed a significant increase in the EE% (P < 0.05) due to increasing drug/polymer 
ratio and increasing the drug concentration available for encapsulation, while there is no 
change in EE% with higher concentration i.e. over 10 mg/mL. NPs with high EE% (loaded 
with 10 mg/mL KT) have been chosen for further characterisation studies. 
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Morphological characterisation of the nanoparticles 
The nanoparticles appeared to be spherical and regular in shape with an average size of 200 
nm (Figure 3). The diameter of the particles is in agreement with the particle size data 
obtained using dynamic light scattering technique. A low polydispersity index (PDI = 0.272 ± 
0.010) further confirmed the homogeneity of the particle size distribution observed in the 
SEM images (Figure 3). 
   
Differential scanning calorimetry (DSC) and FT-IR study 
Figure 4 shows the DSC thermograms of KT, CS, their physical mixture (PM) and drug 
loaded NP formulation (F2KT), loaded with 10 mg/mL KT. The DSC trace of KT shows two 
endothermic peaks at 160oC and 168.9oC. The first peak is associated with the melting of KT 
while the second peak is related to the decomposition of the drug. These results are  in good 
agreement with the data reported previously  (Kavithab et al., 2010); (Chopra et al., 2008). 
On the other hand, the DSC thermogram of CS showed a broad endothermic peak over the 
temperature range 70-100oC which is associated with water loss. The physical mixture of KT 
with CS, showed the same melting behaviour (168.2oC) indicating no chemical interaction 
between the drug and the polymer.  However, the endothermic peak characteristic of KT 
melting was not detected in the thermogram obtained for the KT-loaded NPs which indicates 
chemical interaction and suggests that KT was presumably entrapped within the NPs in the 
amorphous form. 
 The FT-IR spectra for KT, CS, their physical mixture (PM) and drug loaded NP formulation 
(F2KT) loaded with 10 mg/mL KT have been obtained over a range of 4000 - 500 cm ̵1. 
Figure 5 shows major peaks (3,341 cm
-1
; NH stretch, 1,145 cm ̵ 1; C = O stretch 
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(diarylketone), and 1611 cm
-1 
within the spectrum of KT, this is most likely due to C-C 
aromatic stretching). There are three characteristic peaks of CS at 3355 cm ̵ 1 relating to  -OH 
stretching, 2873 cm ̵ 1 corresponding to -CH stretching vibration, 1061 cm ̵ ¹ of C-O-C, and 
1601 cm ̵ 1 of NH2.  The FT-IR spectrum of loaded NPs confirms that the amino groups of CS 
are capable of interacting with anionic groups of TPP by ionic bonding as a primary binding 
force. Also, absence of the characteristic peak of the drug at 3,341 cm
-1
 demonstrates the fact 
that drug-polymer interactions may exist within the NPs. 
Mucoadhesion study 
The stability and interaction of CS-NPs with mucin has been investigated by measuring the 
viscosity of mucin dispersion when incubated at 35
o
C for up to 2 h with KT loaded CS-NPs. 
The viscosity values were also compared with that of CS solution incubated under similar 
conditions. The viscosities of mucin dispersion were not significantly affected or altered (P > 
0.05) by the addition of NP formulation F6KT (loaded with 10 mg/mL KT; Table 3). The 
viscosities of mucin dispersion were 4.73 ± 0.01 cP and 4.64 ± 0.100 cP at 0 and 120 min of 
incubation respectively, compared with viscosity of mucin alone (4.5 ± 0.003 cP). However, 
the viscosity of mucin dispersion showed a significant decrease (P < 0.05) upon incubation 
with CS solution (1.75 mg/mL). Comparing the viscosity values before and after incubation 
i.e. 5.93 ± 0.12 cP and 4.67 ± 0.12 cP at 0 and 120 min respectively. This may be attributed 
to the interaction of negatively charged carboxylic group of mucin with the ionised amino 
group of CS as has been reported previously (De Campos, et al., 2004). According to De 
Campos et al. (2004), this measurement is important as the viscosity is relevant to the 
blinking process which requires a low tear viscosity in order to avoid damage to the corneal 
epithelium. The current data indicates that no change in the viscosity of the tear film may be 
occurring upon instillation of the formulation. It has been reported that increasing viscosity 
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between 12 - 20 cP has doubled the ocular bioavailability, however, excessive increase of 
viscosity did not make any further difference but resisted free movement of eye lids during 
blinking and caused blurred vision. A highly viscous formulation may compromise proper 
instillation of the dosage form and may cause inconvenience during  application (Lang et al., 
2002). 
Comparing the zeta potential values of mucin dispersion before and after incubation, there 
was a small decrease in the zeta potential for mucin + CS:TPP NP formulations (previously 
used in viscosity measurement) compared with mucin + CS solution. Figure 6 indicates that 
the zeta potential of CS solution mixed with mucin before incubation was 66.16 ± 0.21 mV 
and after incubation 61.5 ± 0.11 mV. This significant reduction (P < 0.05) could be related to 
interaction between the negative groups within mucin with the positive groups of CS. On the 
other hand, zeta potential of NPs before and after 2 h incubation was 23.2 ± 0.40 mV and 
22.8 ± 0.41 mV, respectively which appears to be an insignificant change (P > 0.05). Thus, it 
could be concluded from the above data that the prepared NPs have a tendency to interact 
with mucin without altering the corneal viscosity.  
In vitro release study 
The results of KT release from CS-NPs are depicted in Figure 7. The formulation which gave 
the slowest release rate was F3KT, as a complete release of the drug occurred within a period 
of 6 h compared to the release profile of pure KT solution. This formulation had a highest 
EE% of 71.70 ± 1.55 (Table 2). Also, there was no significant difference (P > 0.05) among 
the release patterns of other selected formulations and nearly more than 10% of KT was 
released in the first hour and the total amount of drug was released within 5-6 h compared to 
3h release period for the KT solution. Thus, it was apparent that the NPs showed a more 
retarded drug release.  Interestingly, when the drug release was modelled using the zero 
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order, first order, Hixson-Crowell and Higuchi’s square root of time and Korsmeyer-Peppas 
equations (data not shown) (Shankar & Mishra, 2003), the drug release from the NPs 
resembled a zero order profile.  
As it can be seen from the data (Figure 7), initial burst release of drug from the NPs occurred 
and this rapid release may primarily be due to the surface adsorbed drug that would easily 
diffuse into the release medium (Ji, et al., 2011). According to Agnihotri et al. (2004), drug 
release via diffusion involves three steps. First, water penetrates into particulate system, 
which causes swelling of the matrix; secondly, the conversion of glassy polymer into rubbery 
matrix takes place, while the third step involves the diffusion of the drug from the swollen 
rubbery matrix (Agnihotri, et al., 2004). However, this was not the case for the release pattern 
of these formulations as nearly a steady amount of the drug was released from NPs 
independent of drug concentration entrapped inside the particles.  
 
Physical stability of the prepared nanoparticles  
A long term stability study was carried out by storing the prepared NPs at various 
environmental conditions. Visual inspection of the prepared NPs revealed that, loaded NPs 
stored for 3 months at 4
o
C remained unchanged in terms of colour, absence of particle 
aggregation or sedimentation. Also, there was no change in the pH (pH 5.5). However, NPs 
stored at room temperature (22
o
C), showed some characteristics of aggregation; however, 
upon gentle shaking the formulation reverted to a uniform dispersion, with its pH remaining 
unaltered. From the data in Figure 8, it is clear that the average particle size of the 
formulations showed an insignificant increase (P > 0.05) presumably due to the swelling of 
the NPs at pH 5.5 owing to the presence of the cationic polymer (Lin et al., 2010). On the 
other hand, the samples that were stored at 40
o
C did not show any pH change. However, a 
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colour change i.e. to pale yellow was observed. This might be attributed to high temperature 
storage conditions that affected the drug adsorbed on the surface of NPs. 
On the other hand, upon measuring the drug entrapment efficiency (EE%) of the stored NPs 
(containing 10 mg/mL KT), it was noted that the EE% of loaded CS-NPs stored at 4
o
C, were 
the most stable formulations in terms of drug retention as the data indicated an insignificant 
change (P > 0.05) in the EE% of all the formulations (F2KT, F3KT, and F6KT) compared to 
their counterparts stored at 22
o
C and 40
o
C where the drug retention was significantly lower 
(P < 0.01) (Table 4). Moreover, formulations showed a remarkable decrease in the EE% at 
40
o
C. This stability data indicates that the storage condition of 4
o
C was most suitable for 
storing NPs as they are able to retain their structural and morphological characteristics i.e. 
colour, consistency, pH and also EE%.  
Ex vivo permeation study 
The ex vivo permeation profiles of KT from selected NPs were obtained using excised 
porcine corneas (Figure 9). The NPs have been chosen for corneal permeation study based on 
the size, zeta potential, EE% and physical stability. The following permeation parameters 
were calculated: steady-state flux, apparent permeability coefficient (Papp) and tL (Table 5). 
The steady-state flux calculated for KT solution was 1.9-fold and 2.7-fold higher than those 
from F6KT and F3KT formulations, respectively. It is clear that steady-state flux from KT 
solution was significantly higher (P < 0.001) than that of NP formulations. However, the 
apparent permeability coefficient (Papp) of KT calculated for NPs was significantly (P < 0.05) 
lower than that of free drug solution. In addition, all the three permeation parameters for 
F3KT formulation were significantly (P < 0.05) lower compared to F6KT formulation. The 
permeation parameters obtained from NPs i.e. (F3KT) and (F6KT) was 3.77-fold and 1.89-
fold lower than that for drug solution. These results correlated well with the in vitro release 
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data suggesting that the corneal permeation process of KT was dependent on its release 
characteristics and the permeation across the cornea is rate limiting. 
With regard to the tL data (Table 5), KT solution produced the shortest tL and produced the 
highest steady-state flux. On the other hand, F3KT and F6KT produced longer tL compared to 
KT solution. These results could be attributed to the drug that would take a longer time to 
release from the cross-linked polymer chains within NPs as opposed to free drug solution 
which permeated faster through the cornea. 
  
Conclusion 
The preparation of chitosan based nanoparticles loaded with ketorolac tromethamine in the 
present study had been successful. The DSC chromatograms and FT-IR spectra revealed that 
there was no chemical interaction between drug and CS suggesting that the drug is dispersed 
in a soluble form inside the NPs. The in vitro release study indicated that the prepared 
formulation has the ability to sustain drug release over a period of 6 h as opposed to yielding 
a rapid release profile, noted for KT solution (3 h). Also, the formulation exhibited stability 
and mucoadhesive characteristics when tested with mucin. The stability of NPs was found to 
be temperature dependent, with a lower temperature favouring the formulations. Corneal 
permeation studies confirmed that the prepared NPs have ability to retain the drug on the eye 
surface for longer time compared to the drug solution. Thus, these results demonstrate that 
the chitosan based nanoparticle systems are a promising candidate for the ocular delivery of 
ketorolac tromethamine in terms of improving its efficacy and safety. 
 
 
 
 
 
21 
  
Declaration of interest and acknowledgments 
The authors would like to report that they have no conflicts of interest relevant to the contents 
of this article. This work is undertaken with the financial support from the Culture Affairs 
and Mission Department, Ministry of Higher Education, Cairo, Egypt. 
 References  
Abdelkader, H., Ismail, S., Kamal, H., & Alany, R. G. (2011). Design and evaluation of controlled 
release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm. Sci, 
100, 1833-1846.  
Abdelkader, H., Pierscionek, B., & Alany , R. G. (2014). Novel in situ gelling ocular films for the opioid 
growth factor-receptor antagonist-naltrexone hydrochloride: Fabrication, mechanical 
properties, mucoadhesion, tolerability and stability studies. International Journal of 
Pharmaceutics, 477, 631-642.  
Abdelkader, H., Wu, Z., Al-Kassas, R., & Alany, R. (2012). Niosomes and discomes for ocular delivery 
of naltrexone hydrochloride: Morphological, rheological, spreading properties and photo-
protective effects. International Journal of Pharmaceutics, 433, 142-148.  
Achouri, D., Alhanout, A., Piccerelle, P., & Andrieu, V. (2013). Recent advances in ocular drug 
delivery. Drug Development & Industrial Pharmacy, 39(11), 1599-1617.  
Agnihotri, A. S., Mallikarjuna, N. N., & Aminabhavi, M. T. (2004). Recent advances on chitosan- based 
micro- and nanoparticles in drug delivery. Journal of Controlled Release, 100, 5-28.  
Almeida, H., Amaral, M. H., Lobao, P., & Lobo, J. M. S. (2013). Applications of poloxamers in 
ophthalmic pharmaceutical formulations: an overview. Expert Opin. Drug Deliv. , 10, 1223-
1237.  
Almeida, H., Amaral, M. H., Lobao, P., & Lobo, J. M. S. (2014). In situ gelling : a strategy to improve 
the bioavailability of ophthalmic pharmaceutical formulations. Drug Discovery Today, 19(4), 
400-412.  
Aydın, R. S. T., & Pulat, M. (2012). 5-Fluorouracil Encapsulated Chitosan Nanoparticles for pH-
Stimulated Drug Delivery: Evaluation of ControlledRelease Kinetics. Journal of 
Nanomaterials, 2012, 1-10.  
Calvo, P., Remunan-Ropez, C., Vila-Jato, J. L., & Alonso, M. J. (1997b). Novel hydrophilic chitosan-
polyethylene oxide nanoparticles as protein carriers. Journal of applied polymer science, 63, 
125-132.  
Chopra, D., Sinha, V. R., & Singh, M. (2008). Thermal and Isothermal Methods in Development of 
Sustained Release Dosage Forms of Ketorolac Tromethamine. E-Journal of Chemistry, 5(2), 
316-322.  
De Campos, A. M., Diebold, Y., Carvalho, E. L. S., & Alonso, M. J. (2004). Chitosan nanoparticles as 
new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. 
pharmaceutical research, 21(5), 803-810.  
Di Colo, G., Zambito, Y., Burgalassi, S., Nardini, I., & Saettone, M. F. (2004). Effect of chitosan and of 
N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int. J. 
Pharm., 273, 37–44.  
Fabiano, A., Chetoni, P., & Zambito, Y. (2015). Mucoadhesive nano-sized supramolecular assemblies 
for improved pre-corneal drug residence time. Drug Development & Industrial Pharmacy, 
early view.  
 
 
22 
  
Felt, O., Furrer, P., Mayer, J. M., Plazonnet, B., Buri, P., Gurny, R., Int. J., et al. (1999). Topical use of 
chitosan in ophthalmology: tolerance, assessment and evaluation of precorneal retention. 
Int. J. Pharm., 180, 185–193.  
Gratieri, T., Gelfuso, G. M., Freitas, O. D., Rocha, E. M., & Lopez , R. F. V. (2011). Enhancing and 
sustaining the topical ocular delivery of fluconazole using chitosan solution and 
poloxamer/chitosan in situ forming gel. European Journal of Pharmaceutics and 
Biopharmaceutics, 79(2), 320-327.  
Hafner, A., Lovrić, J., Romić , M. D., Pepić, I., Cetina-Čižmek , B., & Filipović-Grčić. (2015). Evaluation 
of cationic nanosystems with melatonin using an eye-related bioavailability prediction 
model. European Journal of Pharm Sci., 75, 142–150.  
Hassani, S., Laouini, A., Fessi, H., & Charcosset, C. (2015). Preparation of chitosan–TPP nanoparticles 
using microengineeredmembranes – Effect of parameters and encapsulation of tacrine. 
Colloids and Surfaces A: Physicochem. Eng. Aspects 482, 34–43.  
Ji, J., Hao, S., Wu, D., Huang, R., & Xu, Y. (2011). Preparation, characterization and invitro release of 
chitosan nanoparticles loaded with gentamicin and salicylic acid. Carbohydrate polymers, 85, 
803-808.  
Karthikeyan, D., Srinivas M., & C., S. K. (2013). Formulation and evaluation of stavudine 
nanoparticles International journal of novel trends in pharmaceutical sciences, 3(1), 24-32.  
Kaur, I. P., & Smitha, R. (2002). Penetration Enhancers and Ocular Bioadhesives: Two New Avenues 
for Ophthalmic Drug Delivery. Drug Development & Industrial Pharmacy, 28(4), 353-369.  
Kavithab, K., Basu, K. S., & Rupeshumar, M. (2010). Evaluation of Ketorolac Tromethamine 
Microspheres by Chitosan/Gelatin B Complex Coacervation. Scientia  Pharmaceutica, 78, 79-
92.  
Lang, J. C., Roehrs, R. E., Rodeheaver, D. P., Missel, P. J., Jani, R., & Chowhan, M. A. (2002). Design 
and evaluation of ophthalmic pharmaceutical products. In G. S. Banker & C. T. Rhodes (Eds.), 
Modern Phatmaceutics (pp. 626-717). New York, USA: Marcel Dekker. 
Li, X., Du, L., Chen, X., Ge, P., Wang, Y., Fu, Y., et al. (2015). Nasal delivery of analgesic ketorolac 
tromethamine thermo- and ion-sensitive in situ hydrogels. Int J Pharm, 489(1-2), 252–260.  
Lin, T. F., Lin, F. S., Chou, W. H., Yeh, Y. C., Lin, C. P., Fan, S. Z., et al. (2010). Compatibility and 
stability of binary mixtures of ketorolac tromethamine and tramadol hydrochloride injection 
concentrate and diluted infusion solution. Acta Anaesthesiol Taiwan, 48(3), 117-121.  
Ludwig, A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Del. Rev., 57, 
1595– 1639.  
Nagai, N., Yoshioka, C., Mano, Y., Tnabe, W., Ito, Y., . , Okamoto, N., et al. (2015). A nanoparticle 
formulation of disulfiram prolongs corneal residence time of the drug and reduces 
intraocular pressure. Experimental Eye Research, 132, 115-123.  
Ngo, D. H., Vo, T. H., Ngo, D. N., Kang, K. H., Je, J. Y., Pham, H. N. D., et al. (2015). Biological effects of 
chitosan and its derivatives. Food Hydrocolloids, Article in press.  
Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., & Puglisi, G. (2002). Eudragit RS100® 
nanosuspensions for the ophthalmic controlled delivery of ibuprofen. European journal of 
pharmaceutical sciences, 16(1-2), 53-61.  
Qaqish, R. B., & Amiji, M. M. (1999). Synthesis of a fluorescent chitosan derivative and its application 
for the study of chitosan–mucin interactions. Carbohydrate polymers, 38(2), 99–107.  
Rupenthal, I. D., Green, C.R.,  Alany, R.G. (2011). Comparison of ion-activated in situ gelling systems 
for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study. Int 
J Pharm, 411(1-2), 78-85.  
Savaroglu, G., & Genc, L. (2013). Determination of micelle formation of ketorolac tromethamine in 
aqueous media by acoustic measurements. Thermochimica Acta, 552, 5-9.  
Silva, C. A., Nobre, T. M., Pavinatto, F. J., & Jr, O. N. O. (2012). Interaction of chitosan and mucin in a 
biomembrane model environment. Journal of Colloid and Interface Science 376, 289-295.  
 
 
23 
  
Sinha, V. R., Kumar, R. V., & Singh, G. (2009). Ketorolac tromethamine formulations: an overview. 
Expert Opinion on Drug Delivery, 6(9), 961-975.  
Soppimath K.S, Aminabhavi T.M, Kulkarni A.R, & W.E., R. (2001). Biodegradable polymeric 
nanoparticles as drug delivery devices. Journal of Controlled Release, 70, 1-20.  
Sunil, G., Jambulingam, M., Ananda Thangadurai, S., Kamalakannan, D., Sundaraganapathy, R., & 
Jothimanivannan, C. (2013). Development and validation of ketorolac tromethamine in eye 
drops formulation by RP-HPLC method. [Article in press]. Arabian Journal of chemistry, 
Article in press, available online.  
Unlu, N., Kocaoglan, H., Sayin, F., & Hazirolan, D. (2010). Penetration of topically applied diclofenac 
and ketorolac into the aqueous humour and subretinal fluid : rendomized clinical trial. Can 
Journal of Ophalmology, 45(6), 610-615.  
Zhang, H., & Zhao, Y. (2015). Preparation, characterization and evaluation of tea polyphenoleZn 
complex loaded β-chitosan nanoparticles. Food Hydrocolloids, 48, 260-273.  
Zhao, J., & Wu, J. (2006). Preparation and characterization of the fluorescent chitosan nanoparticle 
probe. Chinese Journal of Analytical Chemistry, 34(11), 1555-1559.  
Zhou, H. Y., Hao, J. L., Wang, S., Zheng, Y., & Zhang, S. W. (2013). Nanoparticles in the ocular drug 
delivery. Intternational journal of ophthalmology, 6(3), 390-396.  
Zhu, X., Su, M., Tang, S., Wang, L., Liang, X., Meng, F., et al. (2012). Synthesis of thiolated chitosan 
and preparation nanoparticles with sodium alginate for ocular drug delivery. Molecular 
vision, 18, 1973-1982.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
  
List of Tables: 
 
Table 1: Average particle size, zeta potential and poly dispersity index (PDI) of CS-TPP 
nanoparticles prepared at different concentrations of CS and TPP. Results are expressed as 
mean values ± SD, (n=3).  
 
 
 
*denotes significant difference (P < 0.001) between F6 as well as F7 and other formulations. 
** Significant difference between F3 and F7 (P < 0.001).  
*** PDI variation not significant among different NP formulations (P > 0.05). 
 
 
 
 
 
 
 
 
 
Formulation 
code 
CS 
(mg/mL) 
TPP 
(mg/mL) 
Average 
particle size 
(nm) 
 
Zeta potential    
(mV) 
 
PDI*** 
 
F1 
F2 
F3 
F4 
F5 
F6 
F7 
 
1 
1 
1 
1.25 
1.25 
1.75 
2 
 
0.5 
0.75 
1 
0.5 
0.75 
0.5 
1 
 
108.0 ± 2.4 
110.3 ± 1.8 
141.6 ± 6.8 
151.3 ± 2.5 
175.2 ± 2.0 
181.7 ± 5.6* 
257.2 ± 18.6* 
 
22.9 ± 0.95 
20.1 ± 0.25 
16.6 ± 0.26** 
 
0.274 ± 0.157 
0.165 ± 0.019 
0.157 ± 0.006 
0.205 ± 0.006 
0.111 ± 0.041 
0.115 ± 0.076 
0.152 ± 0.008 
24.4 ± 0.40 
22.3 ± 0.23 
27.8 ± 1.13 
24.8 ± 1.69** 
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Table 2: Effect of ketorolac tromethamine (KT) concentration on the average particle size, 
zeta potential and entrapment efficiency (EE%) of KT loaded CS-TPP nanoparticles. Results 
are expressed as mean values ± SD, (n = 3). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
KT concentration 
5 mg/mL 10 mg/mL 
Formulation 
code 
Average 
particle size 
(nm) 
Zeta potential 
(mV) 
(EE%) 
Average 
particle size 
(nm) 
Zeta potential 
(mV) 
(EE%) 
 
F1KT 
F2KT 
F3KT 
F4KT 
F5KT 
F6KT 
F7KT 
 
 
 
227.4 ± 4.40 
144.5 ± 6.90 
154.9 ± 13.0 
201.8 ± 6.40 
220.0 ± 10.8 
335.5 ± 6.40 
291.9 ± 22.7 
 
21.4 ± 0.21 
19.4 ± 0.87 
13.1 ± 0.40 
15.3 ± 0.12 
16.0 ± 0.21 
24.1 ± 0.95 
18.5 ± 0.98 
 
5.23  ± 2.14 
35.03 ± 4.40 
22.0  ± 3.80 
20.30  ± 1.10 
18.60  ± 0.32 
33.85 ± 7.42 
23.10 ± 3.30 
 
352.9  ± 16.10 
202.2 ± 9.90 
208.8 ± 2.40 
281.5 ± 2.50 
265.2 ± 1.30 
299.5 ± 37.10 
312.1 ± 4.20 
 
20.0 ± 0.31 
16.7 ± 0.42 
16.5 ± 0.15 
21.2 ± 0.52 
21.1 ± 2.10 
23.2 ± 0.65 
17.4 ± 0.68 
 
34.90 ± 0.52 
73.48 ± 7.51 
71.70 ± 1.55 
53.55 ± 8.13 
47.70 ± 4.38 
50.10 ± 0.42 
43.30 ± 0.99 
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Table 3: Viscosity values (cP) of mucin (0.4 mg/mL) before and after incubation with CS 
solution and CS-TPP nanoparticles. Results are expressed as mean values ± SD, (n = 3). 
 
 
 
 
 
 
 
   
 
 
*Significant difference (P < 0.001) between viscosities of (mucin + CS solution) at 5 min and 
at 120 min.  
 N.B. Significant differences (P < 0.001), (P < 0.01) upon comparing viscosities of (mucin + 
CS solution) at 5 min and at 120 min, respectively with mucin on its own as the viscosity of 
mucin alone without any solutions added was found to be (4.5 ± 0.003 cP). 
 
 
 
 
 
 
 
 
 
Viscosity (cP) 
Time (min) Mucin + CS solution Mucin + CS-TPP NPs 
0 5.93 ± 0.12 4.73 ± 0.01 
5 5.92 ± 0.06* 4.73 ± 0.06 
15 5.77 ± 0.06 4.69 ± 0.10 
30 5.35 ± 0.14 4.67 ± 0.03 
60 5.00 ± 0.10 4.66 ±  0.12 
120 4.97 ± 0.12* 4.64 ±  0.10 
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Table 4: Entrapment efficiency (EE%) of different KT (10 mg/mL) loaded nanoparticle 
formulations following their storage at different temperature conditions for three months. 
Results are expressed as mean values ± SD, (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The reduction in the EE% was not significant (P > 0.05) for formulations stored at 4
o
C as 
opposed to their counterparts stored at 22
o
C and 40
o
C over a 3 month period.  
 
 
 
 
 
 
 EE% 
Formulation 
code 
Time period 
(month) 
 4
o
C 22
o
C 40
o
C 
 
 
F2KT 
 
0 
 
3 
  
773.48 ± 7.51* 
 
70.11 ± 0.97 
 
73.48 ± 7.51 
 
62.32 ± 3.54 
 
 
73.48 ± 7.51 
 
60.11 ±  7.33 
 
 
F3KT 
 
0 
 
3 
 
71.70 ± 1.55 
 
69.22 ± 0.94 
 
 
71.70 ± 1.55 
 
67.23 ± 2.33 
 
71.70 ± 1.55 
 
57.23 ± 0.82 
 
 
F6KT 
 
0 
 
3 
 
50.10 ± 0.42 
 
46.12 ± 1.12 
 
 
50.10 ± 0.42 
 
41.33 ± 2.76 
 
50.10 ± 0.42 
 
28.12 ± 9.88 
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Table 5:  Steady-State Flux, Apparent Permeability Coefficient (Papp), and Lag Time (tL) of 
KT. Results are expressed as mean values ± SD, (n = 3). 
 
 
 
 
 
 
              
 
 * A significant difference was noted (P < 0.001) when the data from the three permeation 
parameters between the drug solution and the KT loaded formulations was compared.  
 
 
 
List of Figures: 
Figure 1: Effect of the pH of CS solution on the average particles size of selected CS-TPP 
NPs. Results are expressed as mean values ± SD (n = 3). 
Figure 2: Effect of different concentrations of KT on the EE% of F2 formulation. Results are 
expressed as mean values ± SD (n = 3). 
Figure 3: SEM for F2KT (10 mg/mL KT) loaded CS-NPs. Size bars = 200 nm (A) and 1µm 
(B), respectively. 
Figure 4:  DSC thermograms for KT, CS, their PM and loaded CS-NPs (F2KT). 
 
 
Formulation 
code 
 
Steady-State 
Flux (µg/h) 
 
Papp × 10
-6
 
(cm/sec) 
 
tL (h) 
 
Drug solution 
 
117.65 ± 0.96* 
 
5.31 ± 0.13 
 
0.198 ± 0.34 
 
F3KT 
 
43.70 ± 0.88 
 
1.41 ± 0.24 
 
0.450 ± 0.41 
 
F6KT 
 
62.34 ± 1.25 
 
2.81 ± 0.85 
 
0.483 ± 0.22 
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Figure 5:  FT-IR spectra for KT, CS, their PM and loaded CS-NPs (F2KT). 
 
. 
Figure 6: Zeta potential of mucin solution (0.4 mg/mL), CS solution (1.75 mg/mL), CS 
solution + mucin (1.75 mg/mL) and F6KT NPs + mucin before and after incubation (35
o
C) at 
different time intervals. Results are expressed as mean values ± SD (n=3). 
 
Figure 7: In vitro release profiles of KT from KT-loaded CS-NPs, i.e. F2KT, F3KT and 
F6KT in relation to KT solution. Results are expressed as mean values ± SD (n=3). 
 
Figure 8: Average particle size of different KT-loaded CS-NPs following storage for 3 
months (A) at 22
o
C, (B) at 4
o
C and (C) at 40
o
C. Results are expressed as mean values ± SD 
(n=3). 
Figure 9: Transcorneal permeation profiles of KT-loaded CS-NPs, i.e. F3KT and F6KT in 
relation to KT solution on excised porcine corneas. Results are expressed as mean values ± 
SD (n=3). 
 
 
 
 
 
